Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

First oral blood thinner for children wins FDA approval 

By Brian Buntz | June 21, 2021

Boehringer IngelheimThe FDA has approved Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) oral pellets for children with venous thromboembolism between 3 months and under 12 years old.

The indication stipulates that children receiving Pradaxa have received prior treatment with an injectable blood thinner given by injection for at least five days.

FDA has also approved Pradaxa in capsule form to treat blood clots in patients eight years and older with venous thromboembolism. That approval also requires that the patients receive a prior injectable blood thinner for at least five days. FDA has also approved the use of Pradaxa to prevent recurrent clots in patients eight and older who finished treatment for their first venous thromboembolism.

Besides Pradaxa, there is no other approved oral blood thinner for children.

The drug first won FDA approval in 2010 to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation.

“The FDA is committed to helping our youngest patients with serious medical conditions have treatments that are relatively easy to take,” explained Dr. Ann Farrell, director of the Division of Non-Malignant Hematology in the FDA’s Center for Drug Evaluation and Research, in a statement.

Pradaxa is one of Boehringer Ingelheim’s best-selling products.

In 2020, Pradaxa sales were €1.492 billion ($1.70 billion).

Last November, Boehringer settled 2,935 lawsuits that accused the company of failing to warn patients of potential bleeding risks associated with the drug.


Filed Under: Cardiovascular
Tagged With: Boehringer Ingelheim, dabigatran etexilate, FDA, Pradaxa, venous thromboembolism
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

ChemoCentryx/Amgen
Amgen to pay almost $4B for ChemoCentryx
Astellas Pharma in the Drug Discovery & Development Pharma 50
FDA places clinical hold on Astellas clinical trial focused on Pompe disease
Acer
Acer Therapeutics launches Phase 3 study for vascular Ehlers-Danlos syndrome
AstraZeneca
AstraZeneca’s Farxiga met primary endpoint in Phase 3 heart failure trial 

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50